There is, I think, something ethereal about i —the square root of minus one. I remember first hearing about it at school. It seemed an odd beast at that time—an intruder hovering on the edge of reality.

Usually familiarity dulls this sense of the bizarre, but in the case of i it was the reverse: over the years the sense of its surreal nature intensified. It seemed that it was impossible to write mathematics that described the real world in …

I and i

다중혈관 관상동맥 환자에서 y-문합을 이용하여 양쪽 내흉동맥만을 사용한 우회술의 조기 성적

Human mesenchymal stem cells are thought to be multipotent cells, which are present in adult marrow, that can replicate as undifferentiated cells and that have the potential to differentiate to lineages of mesenchymal tissues, including bone, cartilage, fat, tendon, muscle, and marrow stroma. Cells that have the characteristics of human mesenchymal stem cells were isolated from marrow aspirates of volunteer donors. These cells displayed a stable phenotype and remained as a monolayer in vitro. These adult stem cells could be induced to differentiate exclusively into the adipocytic, chondrocytic, or osteocytic lineages. Individual stem cells were identified that, when expanded to colonies, retained their multilineage potential.

http://science.sciencemag.org/content/sci/284/5411/143.full.pdf

Multilineage Potential of Adult Human Mesenchymal Stem Cells

抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A

[신간의 별자리x] 우리/미술, 그리고 ‘슬픔의 박물관’

During severe sepsis, organ dysfunction is an important predictor of poor outcomes. Animal and human studies suggest that macrophage migration inhibitory factor (MIF) plays a detrimental role in organ dysfunction in severe sepsis. However, MIF is a key mediator of the innate immune response and is necessary for resistance to certain infections. We provide a broad overview of the beneficial and detrimental effects of MIF in sepsis. The interplay between MIF and glucocorticoids, which may play a critical role in sepsis, is also examined.

Macrophage migration inhibitory factor and multiple organ dysfunction syndrome

Immunosuppresive Factors in Cancer

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.38233

In Memoriam: Stephen E. Malawista, MD, 1934–2013

Cette invention concerne un procede de traitement ou de prevention des maladies liees a une surproliferation cellulaire chez un sujet, consistant a administrer au sujet pour lequel le traitement ou la prevention est souhaite, une dose therapeutiquement efficace d'un agent antagoniste de MIF (facteur d'inhibition de la migration des macrophages). Elle concerne egalement un procede de traitement de la neovascularisation tumorale chez un sujet qui consiste a administrer a ce sujet, une dose therapeutiquement efficace d'un agent inhibant ou neutralisant l'activite de MIF.

Utilisation d'antagonistes de mif pour une therapie anti-cancer

This communication is based on a review of the contents of Arthritis and Rheumatism (AR only 9 authors (2%) were not North Americans In contrast, one issue (May 2007) contained 37 full-length articles, 24 authored by nonNorth Americans (Asians, Europeans, Australians) The charge to each past AR before doing that, it is appropriate to comment briefly on the themes that were dominant in work published in the Journal during the early 1970s Coincident with the founding of AR Jane E Salmon, MD: Hospital for Special Surgery, New York, New York; Richard Bucala, MD, PhD: Yale University School of Medicine, New Haven, Connecticut Address correspondence to Charles L Christian, MD, University of Florida Health Science Center, 653 West 8th Street, Jacksonville, FL 32209 E-mail: charleschristian@jaxufledu Submitted for publication September 12, 2007; accepted September 12, 2007

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.23189

Richard Bucala

Papers

Macrophage migration inhibitory factor and multiple organ dysfunction syndrome

Immunosuppresive Factors in Cancer

In Memoriam: Stephen E. Malawista, MD, 1934–2013

Utilisation d'antagonistes de mif pour une therapie anti-cancer

A time capsule for rheumatology.